Last reviewed · How we verify
NCT04225013
Early Diagnosis as Strategy in Reducing the Incidence of Contrast-induced Nephropathy
trial testing Early kidney damage biomarkers in Kidney Injury in 150 participants. Completed in 1 June 2018.
1 June 2018
Quick facts
| Lead sponsor | R. Laura Vicente Vicente |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 June 2015 |
| Primary completion | 1 June 2018 |
| Estimated completion | 1 June 2018 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Early kidney damage biomarkers
- Predisposition to kidney injury biomarkers
Conditions studied
- Kidney Injury — all drugs for Kidney Injury →
- Contrast-induced Nephropathy — all drugs for Contrast-induced Nephropathy →
Sponsor
R. Laura Vicente Vicente
Who can join
Adults 18 to 100, any sex, with Kidney Injury or Contrast-induced Nephropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Renal damage due to contrast media (CM) administration is one of the main complications of cardiac intervention and is called contrast-induced nephropathy (CIN). Patients suffering from CIN have a high probability of developing acute renal failure. Today there is no treatment capable of reversing kidney damage, so the best strategy is prevention, by early diagnosis. In this regard, a line of research is currently being carried out focused on the identification of new markers capable of detecting susceptibility/predisposition to renal damage before the administration of a potentially nephrotoxic drug, even at doses that alone should not produce Kidney damage. This concept has been called predisposition to kidney damage. Taking into account all of the above, the objective of this work is to evaluate the ability of the new markers (previously identified in preclinical models) to detect the predisposition to the CIN before administering the CM.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Albuminuria Pre-Emptively Identifies Cardiac Patients at Risk of Contrast-Induced Nephropathy.
Vicente-Vicente L, Casanova AG, Hernández-Sánchez MT, Prieto M, et al · · 2021 · cited 10× · PMID 34768464 · DOI 10.3390/jcm10214942
Verify or expand the search:
- PubMed search for NCT04225013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Early kidney damage biomarkers
Trials testing the same drug.
- NCT04902846 — Immune Checkpoint Inhibitors Nephrotoxicity · recruiting
- NCT03850756 — Early Diagnosis of Kidney Damage Associated With Tobacco Use · completed
Other recruiting trials for Kidney Injury
Currently open trials in the same condition.
- NCT06585722 — Association Between Venous Excess Ultrasound Grading System and Acute Kidney Injury in the ICU Population · recruiting
- NCT05696444 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) · NA · active not recruiting
- NCT06781476 — Evaluation of Urinary Biomarkers Trend in Preterm Very Low Birth Weight Infants · recruiting
- NCT05283512 — Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanc · NA · recruiting
- NCT04902846 — Immune Checkpoint Inhibitors Nephrotoxicity · recruiting
Other R. Laura Vicente Vicente trials
Trials by the same sponsor.
- NCT04902846 — Immune Checkpoint Inhibitors Nephrotoxicity · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04225013 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by R. Laura Vicente Vicente
- Last refreshed: 25 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04225013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing